MALVERN, Pa., February, 2022 – DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry, is applying its TeleVisit module, a key component of their decentralized trial unified platform, to uniquely solve a common clinical trial challenge.
As the Life Sciences community adapts to decentralized trials and FDA expectations for greater adoption of eSource (Direct Data Entry) trial submissions, it is critical to have the ability to provide fast, flexible technology solutions that are more study participant-centric.
DSG’s eCaseLink unified platform is a single solution that seamlessly combines decentralized trial components Direct Data Capture, eConsent, eCOA, TeleVisit with a clinical trial suite including EDC, RTSM, ePRO, Remote Monitoring, Safety and CTMS to support the unique requirements and workflows of every study protocol. The platform offers a fast and flexible approach to decentralized and traditional clinical trials empowering sites, participants, and every stakeholder.
“I believe that with the emerging need for patient centric solutions, DSG can provide effective TeleVisit solutions to meet our clients’ needs” said Tony Varano, CEO at DSG.
“We applaud our client for effectively using the eCaseLink TeleVisit module to assist their independent call centers and patient needs.”
DSG, Inc. is a leading global eClinical provider with a unified suite of innovative technology solutions for the global clinical research community. DSG's eClinical software platform provides competitive advantage that is cost-effective and quickest to build. DSG’s award-winning eCaseLink solutions are used in thousands of clinical trials around the globe.